[go: up one dir, main page]

MX2020009530A - Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. - Google Patents

Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.

Info

Publication number
MX2020009530A
MX2020009530A MX2020009530A MX2020009530A MX2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A MX 2020009530 A MX2020009530 A MX 2020009530A
Authority
MX
Mexico
Prior art keywords
glycopyranosidase
acetamido
deoxy
glycoprotein
inhibitors
Prior art date
Application number
MX2020009530A
Other languages
English (en)
Inventor
Lei Zhang
Zhili Xin
Nathan Genung
Kevin M Guckian
Jeffrey Vessels
Ryan Gianatassio
Edward Yin Shiang Lin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2020009530A publication Critical patent/MX2020009530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se describen compuestos representados por la fórmula (I''), (Ver Fórmula I). O una sal farmacéuticamente aceptable del mismo, composiciones farmacéuticas que lo comprenden y métodos para preparar y usar los mismos; las variables Ar, Ra, Rb, m, n, Y1, Y2, R3 y R4 se definen en la presente.
MX2020009530A 2018-03-14 2019-03-13 Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. MX2020009530A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862642932P 2018-03-14 2018-03-14
US201862690536P 2018-06-27 2018-06-27
US201862699443P 2018-07-17 2018-07-17
PCT/US2019/021995 WO2019178191A1 (en) 2018-03-14 2019-03-13 O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors

Publications (1)

Publication Number Publication Date
MX2020009530A true MX2020009530A (es) 2021-01-15

Family

ID=65952097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009530A MX2020009530A (es) 2018-03-14 2019-03-13 Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.

Country Status (10)

Country Link
US (1) US20230117898A1 (es)
EP (2) EP3765458B1 (es)
JP (1) JP7453916B2 (es)
CN (2) CN112218863B (es)
AU (1) AU2019234759C1 (es)
CA (1) CA3093315A1 (es)
ES (1) ES2942211T3 (es)
MA (1) MA52004A (es)
MX (1) MX2020009530A (es)
WO (1) WO2019178191A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325535A (zh) * 2017-02-27 2019-10-11 詹森药业有限公司 经哌啶、吗啉或哌嗪取代的作为oga抑制剂的[1,2,4]-三唑[1,5-a]-嘧啶基衍生物
CR20210181A (es) 2018-09-19 2021-07-01 Biogen Ma Inc Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
WO2021094312A1 (en) 2019-11-11 2021-05-20 Janssen Pharmaceutica Nv Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
WO2021110656A1 (en) 2019-12-02 2021-06-10 Janssen Pharmaceutica Nv Oga inhibitor compounds
IL293931A (en) 2019-12-18 2022-08-01 Janssen Pharmaceutica Nv Oga inhibitor compounds
BR112022011812A2 (pt) 2019-12-18 2022-08-30 Janssen Pharmaceutica Nv Compostos inibidores da oga
WO2021123291A1 (en) 2019-12-18 2021-06-24 Janssen Pharmaceutica Nv Oga inhibitor compounds
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도
CN114213315A (zh) * 2021-12-31 2022-03-22 上海陶术生物科技有限公司 含氮杂环类化合物及其中间体的合成方法
CN114560805B (zh) * 2022-01-20 2024-11-29 上海陶术生物科技有限公司 含氮杂环化合物及其中间体的合成方法
CN121405694A (zh) * 2024-07-26 2026-01-27 浙江同源康医药股份有限公司 Oga抑制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2862289C (en) 2012-02-10 2019-11-26 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PL2953941T3 (pl) 2013-02-11 2017-11-30 Constellation Pharmaceuticals, Inc. Modulatory enzymów modyfikujących metyl, ich kompozycje i zastosowania
DK2970272T3 (en) * 2013-03-14 2019-04-23 Merck Patent Gmbh glycosidase
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2015023915A1 (en) 2013-08-15 2015-02-19 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP3389658B1 (en) * 2015-12-18 2020-11-25 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
WO2018109198A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
US20200079766A1 (en) 2016-12-16 2020-03-12 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds
CN110325535A (zh) * 2017-02-27 2019-10-11 詹森药业有限公司 经哌啶、吗啉或哌嗪取代的作为oga抑制剂的[1,2,4]-三唑[1,5-a]-嘧啶基衍生物

Also Published As

Publication number Publication date
AU2019234759B2 (en) 2024-08-01
AU2019234759C1 (en) 2025-02-06
JP2021518340A (ja) 2021-08-02
CN112218863A (zh) 2021-01-12
CN118955490A (zh) 2024-11-15
MA52004A (fr) 2021-01-20
CN112218863B (zh) 2024-07-12
JP7453916B2 (ja) 2024-03-21
EP3765458B1 (en) 2023-01-11
ES2942211T3 (es) 2023-05-30
AU2019234759A1 (en) 2020-09-17
CA3093315A1 (en) 2019-09-19
WO2019178191A1 (en) 2019-09-19
EP4186899A1 (en) 2023-05-31
WO2019178191A8 (en) 2019-12-26
EP3765458A1 (en) 2021-01-20
US20230117898A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
MX2021011606A (es) Compuestos dirigidos a prmt5.
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
CL2019002204A1 (es) Compuestos inhibidores del vih.
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
UY35362A (es) Compuestos terapéuticos
MX2020010508A (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados.
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2022004305A2 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
MX2024009926A (es) Composiciones y metodos para tratar trastornos del snc.
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
UY36124A (es) Derivados de carboxamida
CL2024001047A1 (es) Formas de sal de un receptor del componente c5a del complemento
CO2021017202A2 (es) Compuestos tricíclicos
UY36123A (es) Derivados de carboxamida